The market for novel preventive and acute treatments grew from three anti-CGRP antibodies at the start of 2020 to four biologics and two oral drugs against CGRP plus a small molecule 5-HT1F inhibitor. 

AbbVie's Rinvoq has performed well in the second of three Phase III studies evaluating its potential treatment for atopic dermatitis, further boosting chances the JAK1 inhibitor will become a blockbuster in that indication.

With a complete response letter for wet AMD drug abicipar, AbbVie is expected to move on from the drug acquired with Allergan. Molecular Partners now seems inclined to focus on IO, virology.